drug
as of 2026-07-01topiramate
Topiramate
MeSH D000077236
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Johnson & Johnson
6 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
6
Topiramate and Schizophrenia: Effects on Weight and Psychopathology
NCT02808533—Active Not Recruiting
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
NCT05663749Phase 4Completed
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
NCT00240721Phase 3Completed
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
NCT00035802Phase 3Completed
Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
NCT00237289Phase 3Completed
KOLs & investigators
3
Margaret K Hahn, PhD, MDKOL score 10
Helge Frieling, Prof., MDKOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Margaret K Hahn, PhD, MD
personKOL score 10
Helge Frieling, Prof., MD
personKOL score 5
Biswa Ranjan Mishra, MD, DPM
personKOL score —